Almac Group

Northern Ireland CDMO, privately held. Founded 1969, headquartered in Craigavon. Over £400M ($500M) expansion program completed 2024, including new 28,000 sq ft GMP peptide API facility doubling capacity. MHRA audited. Offers peptide synthesis from research to commercial scale.

Almac Group is listed as a CDMO in the peptide supply chain, serving Europe markets from UK (NI). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. Verification is supported by 4 independent sources, including documentation review and cross-referencing against public records. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.